Research Article: Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
Abstract:
Introduction: Sézary syndrome (SS) is an aggressive variant of cutaneous T-cell lymphoma (CTCL) that presents with generalized erythroderma, lymphadenopathy, peripheral blood involvement, and severe pruritus. Unfortunately, the disease can relapse or progress and generally has a poor prognosis. Mogamulizumab is a targeted monoclonal antibody that has been shown to be effective in relapsed disease, with particular benefit in the blood compartment, and has received the U.S. Food and Drug Administration (FDA) approval for CTCL. Data regarding the combination of mogamulizumab with other systemic treatments for CTCL are limited. Here, we present clinical outcomes in a real-world setting where patients with SS were treated using a mogamulizumab-based multi-agent approach.
No summary available.